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Introduction: C-reactive protein (CRP) is one of the biomarkers for the diagnosis and assessment of disease activity
in rheumatoid arthritis (RA). CRP is not only the by-product of inflammatory response, but also plays proinflammatory
and prothrombotic roles. The aim of this study was to determine the role of CRP on bone destruction in RA.
Methods: CRP levels in RA synovial fluid (SF) and serum were measured using the immunoturbidimetric method.
The expression of CRP in RA synovium was assessed using immunohistochemical staining. CD14+ monocytes from
peripheral blood were cultured with CRP, and receptor activator of nuclear factor-κB ligand (RANKL) expression
and osteoclast differentiation were evaluated using real-time PCR, counting tartrate resistant acid phosphatase
(TRAP)-positive multinucleated cells and assessing bone resorbing function. CRP-induced osteoclast differentiation
was also examined after inhibition of Fcγ receptors.
Results: There was a significant correlation between CRP levels in serum and SF in RA patients. The SF CRP level
was correlated with interleukin (IL)-6 levels, but not with RANKL levels. Immunohistochemical staining revealed
that compared with the osteoarthritis synovium, CRP was more abundantly expressed in the lining and sublining
areas of the RA synovium. CRP stimulated RANKL production in monocytes and it induced osteoclast
differentiation from monocytes and bone resorption in the absence of RANKL.
Conclusions: CRP could play an important role in the bony destructive process in RA through the induction of
RANKL expression and direct differentiation of osteoclast precursors into mature osteoclasts. In the treatment of
RA, lowering CRP levels is a significant parameter not only for improving disease activity but also for preventing
bone destruction.Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory
disease characterized by synovitis of peripheral joints and
subsequent joint destruction. Assessment of disease activ-
ity is based on the count of tender and swollen joints, the
measurement of erythrocyte sedimentation rate (ESR) or
serum levels of acute phase reactants such as C-reactive
protein (CRP), and the pain score of patients [1-3]. The
new classification criteria for RA including ESR and CRP
measurements allow early aggressive treatment of RA
[4,5]. As an inflammatory biomarker for RA, CRP corre-
lates with disease activity, histological changes in the
synovium, and radiological progression, responding very* Correspondence: kimhaerim@kuh.ac.kr
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stated.quickly to changes in disease activity [6-10]. In terms of
clinical parameters, CRP level correlates with morning
stiffness, pain, fatigue, grip strength, articular index, and
disability [7]. Moreover, CRP level is not affected by age,
gender, and abnormalities in erythrocytes and serum
proteins. Hence, among various parameters, CRP is the
most reliable and objective measure and a useful prog-
nostic factor for disease progression to joint damage
and functional outcome [11-13].
CRP is a member of the pentraxin protein family, which
is composed of five 23-kDa subunits and it can increase
by 1,000-fold or more with infection, inflammation, and
tissue injury [14,15]. Interleukin (IL)-6, IL-1β, and tumor
necrosis factor (TNF)-α promote the synthesis of CRP in
hepatocytes [15,16]. While hepatocytes are main sources
of CRP, monocytes, lymphocytes, adipocytes, neurons, and
vascular smooth muscle cells are the extrahepatic sources
of CRP [17-19]. To eliminate infectious microorganismsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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complement cascade and stimulates the influx and phago-
cytic activity of neutrophils [20,21]. In addition to clearing
infection, CRP plays a regulatory role in inflammation and
atherosclerotic thrombosis. It stimulates endothelial cells
to produce intercellular adhesion molecule (ICAM)-1,
vascular cell adhesion molecule (VCAM)-1, E-selectin,
and monocyte chemotactic protein (MCP)-1 and in-
hibits the expression of endothelial nitric oxide synthase
[22-24]. Interaction of CRP with Fcgamma receptor
(FcγR)I and FcγRIIA also promotes the production of
proinflammatory cytokines, resulting in the amplifica-
tion loop of inflammatory reaction [25]. Until now, CRP
has been in the spotlight as a marker of disease activity
and a by-product of inflammatory reactions in RA.
However, it is possible that CRP is one of the proinflam-
matory and bone destruction molecules in the patho-
genesis of RA.
In this study, we hypothesized that CRP not only re-
sults from the inflammation process, but also triggers
proinflammatory responses and bone destruction. These
processes are initiated through the induction of the recep-
tor activator of nuclear factor-κB ligand (RANKL) protein
and direct stimulation of osteoclastogenesis, causing a vi-
cious loop between inflammation and bone destruction in
RA. We studied the effects of CRP on the induction of
RANKL and osteoclast differentiation from peripheral
blood monocytes. We found that CRP induced RANKL
expression in peripheral blood monocytes and osteoclast
precursors and stimulated these cells to differentiate into
osteoclasts. In the treatment of RA, the reduction of CRP
level reflects not only the control of disease activity, but
also the prevention of bone destruction.Materials and methods
Patients
Synovial tissues were obtained from seven patients with
RA (mean age 63.4 ± 4.6 years) and five patients with
osteoarthritis (OA) (mean age 56.6 ± 4.7 years), who were
undergoing total knee replacement surgery. Synovial fluid
and serum were obtained from 20 RA patients who ful-
filled the 1987 revised criteria of the American College of
Rheumatology [26]. Informed consent was obtained from
all patients, and the experimental protocol was approved
by the Konkuk University Medical Center Human Re-
search Ethics Committee.Reagents
Recombinant CRP was supplied by Sigma-Aldrich, St
Louis, MO, USA. Recombinant macrophage colony-
stimulating factor (M-CSF) was purchased from R&D
Systems (Minneapolis, MN, USA). Anti-CD64, anti-CD32
and anti-CD16 were obtained from R&D Systems. Humanimmunoglobulin G (IgG) was purchased from Green
Cross Corp. (Yong-In, Korea).
Measurement of CRP
High-sensitivity CRP was measured by an immunotur-
bidimetric method (CRP II Latex X2, Denka Seiken Co.
Ltd., Tokyo, Japan) using an autoanalyzer (Toshiba,
Tokyo, Japan). Measurement range of this assay is 0.01
to 32 mg/dL.
Enzyme-linked immunosorbent assay of RANKL, IL-6, IL-1β
and TNF-α
Briefly, a 96-well plate (Nunc) was coated overnight with
4 μg/ml monoclonal antibodies against RANKL, IL-6,
IL-1β and TNF-α (R&D Systems) at 4°C. After blocking
with phosphate-buffered saline (PBS)/1% bovine serum
albumin (BSA)/0.05% Tween 20 for 2 hours at room
temperature (22 to 25°C), the test samples and standard
recombinant RANKL, IL-6, IL-1β and TNF-α were added
to the 96-well plate and incubated at room temperature
for 2 hours. The plates were washed four times with PBS/
Tween 20, and then incubated with 500 ng/ml biotinyl-
ated mouse monoclonal antibodies against RANKL, IL-6,
IL-1β and TNF-α for 2 hours at room temperature. After
washing, streptavidin-alkaline phosphate-horseradish per-
oxidase conjugate (Sigma-Aldrich) was added and the
plate was incubated for 2 hours, after which the plate was
washed again and incubated with 1 mg/ml p-nitrophenyl
phosphate (Sigma-Aldrich) dissolved in diethanolamine
(Sigma-Aldrich) to develop the color reaction. The reac-
tion was quenched by the addition of 1 M NaOH, and the
optical density of each well was read at 405 nm. The lower
detection limit of RANKL, IL-6, IL-1β and TNF-α was
10 pg/ml. Recombinant human RANKL, IL-6, IL-1β and
TNF-α were diluted in the culture medium and used as
the calibration standard with concentration of 10 to
2,000 pg/ml. A standard curve was drawn by plotting
the optical density as a function of the log of the con-
centration of recombinant cytokines, and was used to
calculate the RANKL, IL-6, IL-1β and TNF-α concen-
trations in the test samples.
Immunohistochemical analysis of RA synovial tissues
Immunohistochemical staining for CRP was performed
on sections of synovial tissues. Briefly, synovial tissues
were obtained from patients with RA and OA, fixed with
4% paraformaldehyde solution overnight at 4°C, dehy-
drated with a graded series of alcohol, washed, embed-
ded in paraffin, and cut into 7-μm thick sections. The
sections were depleted of endogenous peroxidase activity
by adding methanolic H2O2 and blocked with normal
serum for 30 minutes. After overnight incubation at 4°C
with polyclonal anti-human CRP antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), the samples were
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anti-rabbit IgG, for 20 minutes and incubated with the
streptavidin-peroxidase complex (Vector Laboratories
Ltd., Peterborough, UK) for 1 hour followed by incubation
with 3,3′-diaminobenzidine (Dako, Glostrup, Denmark)
for 5 minutes. The sections were counterstained with
hematoxylin. The samples were photographed using an
Olympus photomicroscope (Tokyo, Japan). For the evalu-
ation of immunohistochemistry slides using ImageJ (NIH,
Bethesda, MD, USA), images are captured onto the hard
drive of the workstation computer. Thereafter, captured
images are opened in NIH Image/ImageJ for evaluating in-
dices of positivity on immunohistochemistry slides.
Monocyte isolation
Peripheral blood mononuclear cells (PBMC) were
separated by Ficoll-Hypaque (Sigma-Aldrich) density gra-
dient centrifugation from the buffy coats obtained from
healthy volunteers. The cells were washed three times
with sterile PBS and resuspended in RPMI 1640 (Life
Technologies, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1%
penicillin-streptomycin, henceforth called complete
medium. Freshly isolated PBMC were incubated at 37°C
in complete medium and allowed to adhere for 45 -
minutes. The nonadherent cells were removed and the
adherent cells were washed with sterile PBS, harvested
with a rubber policeman, and stained with the
monocyte-specific anti-CD14 monoclonal antibody to
assess the purity of the preparation. Ninety percent of
the isolated cells expressed CD14. The osteoclast precur-
sors were prepared using the monocytes-enriched frac-
tion from the peripheral blood.
Expression of target mRNA determined by real-time PCR
with SYBR Green I
Monocytes were stimulated with various CRP concentra-
tions (0.1, 0.5, or 1 ug/ml). For signal pathway analysis
of RANKL, the monocytes were incubated in the pres-
ence or absence of anti-CD64, anti-CD32 and anti-CD16
(10 ng/ml) for 1 hour before the addition of recombinant
human (rh) CRP (rhCRP). After incubation for 12 hours,
mRNA was extracted using RNAzol B (Biotex Laborator-
ies, Houston, TX, USA) according to the manufacturer’s
instructions. The reverse transcription of 2 μg of total
mRNA was performed at 42°C using the Superscript™
reverse transcription system (Takara Bio Inc., Shiga,
Japan). Real-time PCRs were performed in 20-μl final
volumes in capillary tubes in a LightCycler instrument
(Roche Diagnostics, Mannheim, Germany). The follow-
ing primers were used for each molecule: for RANKL,
5′-ACC-AGC-ATC-AAA-ATC-CCA-AG-3′ (sense) and
5′-CCC-CAA-AGT-ATG-TTG-CAT-CC-3′(antisense); for
FcγR1a, 5′-TGA-GGT-GTC-ATG-CGT-GGA-A-3′ (sense)and 5′-GGT-AGG-TGC-CAT-TGT-GAC-TTA-TG-3′
(antisense); for FcγR2a, 5′-ATC-ATT-GTG-GCT-GTG-
GTC-ATT-G-3′ (sense) and 5′-CCA-ACA-ATG-ACT-
ATG-AAA-CAG-CTG-AC-3′ (antisense); for FcγR2b,
5′-CCT-GAT-GAC-CAG-AAC-CGT-ATT-TAG-T-3′
(sense) and 5′-TTT-TGG-TTC-TGC-AGC-ATC-TCC-
3′ (antisense); for CTR, 5′-TGG-TGC-CAA-CCA-CT
A-TCC-ATG-C-3′ (sense) and 5′-CAC-AAG-TGC-C
GC-CAT-GAC-AG-3′ (antisense); for cathepsin K, 5′-
TGA-GGC-TTC-TCT-TGG-TGT-CCA-TAC-3′ (sense)
and 5′-AAA-GGG-TGT-CAT-TAC-TGC-GGG-3′ (anti-
sense); for MMP-9, 5′-CGC-AGA-CAT-CGT-CAT-CCA-
GT-3′ (sense) and 5′- GGA-TTG-GCC-TTG-GAA-GA
T-GA-3′ (antisense); for RANK, 5′-GCT-CTA-ACA-A
AT-GTG-AAC-CAG-GA-3′ (sense) and 5′-GCC-TTG-
CCT-GTA-TCA-CAA-ACT-3′ (antisense); for TRAP,
5′-GAC-CAC-CTT-GGC-AAT-GTC-TCT-G-3′ (sense)
and 5′-TGG-CTG-AGG-AAG-TCT-CTG-AGT-TG-3′
(antisense); for DC-STAMP, 5′-TTC-GCT-CGT-CCT-
GCT-TGG-3′ (sense) and 5′-GCG-GGA-TGT-CTG-
GTG-ATG-TAG-3′ (antisense); for MFR, 5′-CCC-AG
G-GCT-CCA-CTT-CTT-C-3′ (sense) and 5′-TGT-GG
T-TGT-TGG-GCT-CCG-3′ (antisense); for β-actin, 5′-
GGA-CTT-CGA-GCA-AGA-GATGG- 3′ (sense) and 5′-
TGT-GTT-GGC-GAT-CAG-GTCTTT- G-3′ (antisense).
Reaction mixtures contained 2 μl of LightCycler Fas-
tStart DNA mastermix for SYBR Green I (Roche Diag-
nostics), 0.5 μM each primer, 4 mM MgCl2, and 2 μl of
template DNA.
All capillaries were sealed, centrifuged at 500 g for
5 seconds, and then amplified in a LightCycler instrument,
with activation of polymerase (95°C for 10 minutes),
followed by 45 cycles of 10 seconds at 95°C, 10 seconds at
60°C, and 10 seconds at 72°C.
The temperature transition rate was 20°C/second for
all steps. Double-stranded PCR product was measured
during the 72°C extension step by detection of fluores-
cence associated with the binding of SYBR Green I to the
product. Fluorescence curves were analyzed with LightCy-
cler software, version 3.0. For quantification analysis of
target mRNA, LightCycler was used. Relative expression
levels of samples were calculated by normalizing target
levels to the endogenously expressed housekeeping gene
(beta-actin). Melting curve protocol under the following
conditions: 0 second (hold time on reaching temperatures)
at 95°C, 15 seconds at 65°C, and 0 second (hold time) at
95°C. The temperature change rate was 20°C/second, ex-
cept in the final step, in which it was 0.1°C/second. The
melt peak generated represented the specific amplified
product. The crossing point was defined as the maximum
of the second derivative from the fluorescence curve.
Negative controls, which contained all the elements of the
reaction mixture except template DNA, were also in-
cluded. All samples were processed in duplicate.
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Monocytes were incubated with CRP. After incubation
for 72 hours, whole-cell lysates were prepared from
about 5 × 106 cells by homogenization in the lysis buffer,
and centrifuged at 14,000 rpm for 15 minutes. The pro-
tein concentration in the supernatant was determined
using the Bradford method (Bio-Rad, Hercules, CA,
USA). Protein samples were separated on 10% sodium
dodecyl sulfate-polyacrylamide electrophoresis (SDS-
PAGE), and transferred to a nitrocellulose membrane
(Amersham Pharmacia Biotech, Uppsala, Sweden). For
western hybridization, the membrane was preincubated
with 0.5% skim milk in 0.1% Tween 20 in Tris-buffered
saline (TTBS) at room temperature for 2 hours. The pri-
mary antibody to p-syk, p-Akt, Akt, p-ERK, ERK, p-JNK,
JNK, p-p38, p38, beta-actin (Cell Signaling Beverly, MA,
USA), diluted 1:1000 in 5% BSA-0.1% Tween 20/TBS, was
added and incubated for overnight at 4°C. The membrane
was washed four times with TTBS, and horseradish
peroxidase-conjugated secondary antibody was added
and incubated for 1 hour at room temperature. After
TTBS washing, hybridized bands were detected using
the ECL detection kit and Hyperfilm-ECL reagents
(Amersham Pharmacia).
Osteoclast differentiation
PBMC were isolated by Ficoll-Hypaque (Sigma-Aldrich,
Poole, Dorset, UK) density gradient centrifugation from
the buffy coats obtained from healthy volunteers. The
cells were washed three times with sterile PBS and resus-
pended in RPMI 1640 (Life Technologies) supplemented
with 10% FBS, 2 mM L-glutamine, and 1% penicillin-
streptomycin (complete medium). Freshly isolated PBMC
were incubated at 37°C in complete medium and allowed
to adhere for 45 minutes. The nonadherent cells were re-
moved and the adherent cells were washed with sterile
PBS, harvested with a rubber policeman, and stained with
monocyte-specific anti-CD14 monoclonal antibody to as-
sess the purity of the preparation. Ninety percent of the
isolated cells expressed CD14. The osteoclast precursors
were prepared using the monocyte-enriched fraction from
the peripheral blood. The cells were cocultured for three
weeks in minimal essential medium (MEM)-α and 10%
heat-inactivated FBS in the presence of 25 ng/ml rhM-
CSF. The medium was changed on day 3 and then every
other day thereafter. On day 21, tartrate-resistant acid
phosphatase (TRAP)-positive cells were identified using a
leukocyte acid phosphatase kit according to the manufac-
turer’s protocol (Sigma-Aldrich).
Bone resorbing function assay
We performed an in vitro resorption pit assay using a
bone resorption assay kit (Cosmo Bio Co., Ltd., Tokyo,
Japan). Monocytes were cultured on a bone-coated platewith M-CSF in the presence or absence of various con-
centration of CRP for 14 days. The cells were removed
from a bone-coated plate by wiping the surface of it.
The number of pits formed by bone resorption on the
plate was counted.
Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM). Statistical differences were assessed using
one-way or two-way repeated-measures analysis of vari-
ance (ANOVA), followed by the Dunnett’s multiple com-
parison test or Student’s t test for comparison of each
group. A P value <0.05 was considered significant.
Results
CRP levels in RA serum and SF and their correlation with
RANKL
Serum and synovial fluid (SF) CRP levels of 20 RA pa-
tients were measured using an immunoturbidimetric
method. The clinical characteristics of the RA patients are
as follows: 17 females and 3 males, age 57.5 ± 3.7 years
(range: 26 to 87 years), disease duration 3.5 ± 0.7 years
(range: 0.1 to 12 years), ESR 51.1 ± 7.1 mm/h (range: 8 to
116 mm/h, normal <15), serum CRP 2.7 ± 0.3 mg/dL
(range: 0.5 to 5.6 mg/dL, normal <0.3), SF CRP 1.9 ±
0.2 mg/dL (range: 0.5 to 4.7 mg/dL), rheumatoid factor
70.9 ± 16.9 IU/mL (range: 3 to 266 IU/mL, normal <18)
and anti-cyclic citrullinated protein antibody 64.1 ± 23.6
U/mL (range: 0.3 to 338 U/mL, normal <5). In 20 OA pa-
tients, the serum CRP level was 0.08 ± 0.02 mg/dL (range:
0.01 to 0.3 mg/dL) and the SF CRP level was 0.04 ±
0.01 mg/dL (range: 0.02 to 0.09 mg/dL); these values were
significantly lower than those in RA patients (P <0.005,
data not shown). There was no difference of SF CRP levels
between the patients who were taking steroids and the pa-
tients who did not (9.23 mg/dl vs. 11. 67 mg/dl, P = 0.38).
There was significant positive correlation between serum
and SF CRP levels in RA patients (R2 = 0.58, P <0.05,
Figure 1A). Both serum and SF CRP levels were corre-
lated with the SF IL-6 level (R2 = 0.78, P <0.005 and
R2 = 0.62, P <0.05, respectively); however, there was no
correlation between SF CRP and SF RANKL levels
(Figure 1B, C). Immunohistochemical staining revealed
that compared with the OA synovium, CRP was more
abundantly expressed in the lining and sublining areas
of the RA synovium (Figure 1D, E).
The effect of CRP on the expression of RANKL mRNA in
osteoclast precursors
After peripheral blood CD14+ monocytes were stimulated
with various doses of CRP, RANKL mRNA expression and
protein production were determined using real-time PCR
and enzyme-linked immunosorbent assay (ELISA) in the
culture medium, respectively. CRP increased the expression
Figure 1 The expression of CRP in serum, synovial fluid (SF), and synovial tissues of RA patients. (A) SF and serum of 20 RA patients were
collected and CRP level was measured using an immunoturbidimetric method. There is significant correlation between SF and serum levels of
CRP (R2 = 0.58, P <0.05). (B) SF IL-6 and IL-6 levels were measured using sandwich ELISA. SF CRP level is correlated with SF IL-6 level (R2 = 0.62,
P <0.05). (C) There is no correlation between SF CRP and SF RANKL levels in RA patients. (D) Immunohistochemical staining for CRP in the
synovium of patients with RA and osteoarthritis (OA) shows abundant expression of CRP in the synovial lining and sublining areas in RA synovium,
while there is minimal expression of CRP in OA synovium (original magnification: 200× and 400×). The figures are representatives of three independent
experiments. (E) The quantitative measurement of positive area using ImageJ is larger in RA synovium than OA synovium (original magnification;
400×). **P <0.01. CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; RA, rheumatoid arthritis; RANKL, receptor
activator of nuclear factor kappa-B ligand.
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imal effect at a concentration of 1 μg/mL (Figure 2A). In
the culture medium, the production of RANKL also in-
creased with CRP stimulation, following a pattern similar
to that of the gene expression (Figure 2B). However, CRP
did not induce the production of proinflammatory cyto-
kines such as IL-1β, TNF-α, or IL-6 (Figure 2C).
Mediation of Fcgamma receptors (FcγRs) I and II in the
CRP-induced RANKL expression
To define the predominant receptor involved in the CRP-
induced RANKL expression, peripheral blood monocytes
were cultured with CRP in the presence of FcγR inhibi-
tors. After the monocytes were cultured with anti-FcγRI
(CD64), anti-FcγRIIA (CD32), or anti-FcγRIIB (CD16) in
the presence of CRP, the gene expression of RANKL de-
creased with all three receptor inhibitors (Figure 3A). Theexpression of FcγRI, FcγRIIa and FcγRIIb was significantly
increased by CRP stimulation (Figure 3B). To define
downstream pathways of the FcγR, the phosphorylation
of Syk, Akt, ERK, JNK and p38 was determined by
Western blot analysis and CRP increased the phosphor-
ylation of Syk, Akt, ERK and JNK (Figure 3C).
The effect of CRP on osteoclast differentiation
Peripheral blood monocytes can differentiate into TRAP+
multinucleated osteoclasts in the presence of RANKL and
M-CSF [27]. To determine the direct and independent
effect of CRP on the induction of osteoclastogenesis, per-
ipheral blood CD14+ monocytes were isolated and cul-
tured with CRP and M-CSF in the absence of RANKL.
After 21 days of culture, TRAP+ multinucleated osteo-
clasts were differentiated from the monocytes in a dose-
dependent manners and functional bone resorption was
Figure 2 CRP-induced RANKL expression and production in peripheral blood monocytes. (A) After peripheral blood CD14+ monocytes
were cultured with 0 to 1.0 μg/mL of CRP for 72 h, the expression of RANKL mRNA was determined using real-time PCR. The expression of RANKL
mRNA increased in a dose-dependent manner with a maximal effect at 1.0 μg/mL of CRP. (B) In monocytes cultured with CRP, the production
of RANKL was measured using sandwich ELISA. CRP also increased RANKL production of cultured monocytes in a dose-dependent manner.
(C) After peripheral blood CD14+ monocytes were cultured with CRP for 72 h, the concentrations of IL-1β, TNF-α, and IL-6 in culture media were
determined using sandwich ELISA. CRP does not stimulate monocytes to produce IL-1β, IL-6, or TNF-α. The data represents the mean ± SEM for
three independent experiments; *P <0.05, **P <0.01. CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; RANKL,
receptor activator of nuclear factor kappa-B ligand; SEM, standard error of the mean; TNF, tumor necrosis factor.
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did not contain RANKL. CRP stimulated osteoclast differ-
entiation in a dose-dependent manner (Figure 4A) and the
CRP-induced osteoclastogenesis and bone resorbing func-
tion were reduced incompletely by inhibition of RANKL
(Figure 4A, B). The gene expressions of TRAP, cathepsin
K, matrix metalloproteinase (MMP)-9, and RANK also in-
creased in the differentiated osteoclasts (Figure 4C).
Mediation of FcγRs in the CRP-induced osteoclastogenesis
After the monocytes were cultured with anti-CD64,
anti-CD32, or anti-CD16 in the presence of CRP and M-
CSF, the CRP-induced osteoclast differentiation were
partially decreased (Figure 5A). The gene expressions of
osteoclast fusion proteins and dendritic cell-specific trans-
membrane protein (DC-STAMP) decreased with all inhib-
itors, and the gene expression of MFR decreased with the
inhibitors of FcγRI and FcγRIIa (Figure 5B). The gene ex-
pression of RANK, MMP and cathepsin K also decreased
with all three inhibitors and the gene expression ofcalcitonin receptor (CTR) decreased with the FcγRI in-
hibitor (Figure 5C).
The effect of a representative FcγR ligand, IgG, on RANKL
expression and osteoclast differentiation
FcγRs are receptors for the Fc portion of immunoglobu-
lins, we compared the effect of CRP with IgG on RANKL
expression and osteoclastogenesis. Human IgG also stimu-
lated peripheral blood monocytes to express RANKL
mRNA, but CRP showed larger impact on the RANKL ex-
pression than IgG (Figure 6A). After the monocytes were
cultured with anti-CD64, anti-CD32, or anti-CD16 in the
presence of IgG, the gene expression of RANKL decreased
with all three receptor inhibitors (Figure 6B). IgG, in the
presence of M-CSF, also induced TRAP+ multinucleated
osteoclasts from the monocytes and bone resorption,
however, the number of TRAP+ osteoclasts from the
culture of IgG was smaller than that from the culture of
CRP (Figure 6C). The gene expressions of TRAP, ca-
thepsin K, MMP-9, and RANK also increased in the
Figure 3 The effect of FcγR on CRP-induced RANKL expression in monocytes. (A) Peripheral blood CD14+ monocytes were pretreated with
anti-CD64 (FcγRI inhibitor), anti-CD32 (FcγRIIa inhibitor), or anti-CD16 (FcγRIIb inhibitor) for 1 h and were cultured with 1 μg/mL of CRP for 72 h.
The expression of RANKL mRNA was determined using real-time PCR. The expression of RANKL mRNA decreased after inhibition of FcγRI, FcγRIIa,
and FcγRIIb. (B) After peripheral blood CD14+ monocytes were cultured with 1 μg/mL of CRP for 72 h, the gene expressions of FcγRI, FcγRIIa,
and FcγRIIb were determined using real-time PCR. The expressions of FcγRI, FcγRIIa and FcγRIIb mRNA were increased by CRP stimulation.
(C) CRP-induced expression of intracellular signal molecules was determined by Western blotting. The amount of protein expression was normalized
to beta-actin, and the ratio of the phosphorylated form to the total form was calculated. CRP increased the phosphorylation of Syk, Akt, ERK and JNK.
The data represents the mean ± SEM for three independent experiments; *P <0.05 and **P <0.01. CRP, C-reactive protein; FcγR, Fcgamma receptors;
RANKL, receptor activator of nuclear factor kappa-B ligand; SEM, standard error of the mean; TNF, tumor necrosis factor.
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the stimulatory effects of IgG were also smaller than
CRP (data not shown).
Discussion
In RA, high CRP levels correlate to rapid and severe
progression of joint damage in one year, and persistently
high CRP levels are associated with substantial progres-
sion in radiological joint damage [12]. Because CRP plays
a pathogenic role in the inflammation observed in RA, itis possible that CRP is associated with the bony destruc-
tive process in the pathogenesis of RA. However, the
pathogenic mechanisms of CRP in bone destruction have
not been investigated. In this study, we studied the role of
CRP on bone destruction of RA, especially its effect on
RANKL production and osteoclast differentiation.
To determine CRP expression in the synovial tissues,
we measured CRP levels in the SF and synovium of RA
patients. SF CRP levels were higher in RA patients than
in OA patients. There was a strong correlation between
Figure 4 CRP-induced osteoclast differentiation from CD14+ monocytes isolated from peripheral blood. (A) CD14+ monocytes, which
were isolated from peripheral blood, were cultured with 25 ng/mL of M-CSF and 0 to 1.0 μg/mL of CRP in the presence or absence of anti-RANKL.
After 21 days of culture, TRAP-positive multinucleated cells were counted. TRAP+ multinucleated osteoclasts were differentiated from the monocytes
in a dose-dependent manner with a maximal effect at 1.0 μg/mL of CRP and anti-RANKL partially reduced the CRP-induced osteoclastogenesis.
The figures represent one of three independent experiments (original magnification: 200×). (B) Monocytes were cultured on a bone-coating
plate with M-CSF, CRP and anti-RANKL for 21 days. The number of pits formed by bone resorption on the plate was counted. CRP significantly
increased the bone resorbing function and this CRP-induced bone resorption was incompletely inhibited by neuralization of RANKL. The figures
represent one of three independent experiments (original magnification: 200×). (C) The gene expressions of osteoclast markers such as TRAP,
cathepsin K, CTR, MMP-9, and RANK were measured from differentiated osteoclasts using real-time PCR. The gene expressions of TRAP, cathepsin K,
MMP-9, and RANK increased significantly with CRP stimulation. The data represents the mean ± SEM for three independent experiments; *P <0.05 and
**P <0.01. CRP, C-reactive protein; M-CSF, macrophage colony-stimulating factor; MMP, matrix metalloproteinases; RANKL, receptor activator of nuclear
factor kappa-B ligand; SEM, standard error of the mean; SF, synovial fluid; TRAP, tartrate-resistant acid phosphatase.
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CRP level was similar and correlated to the SF CRP
level, suggesting that elevated SF CRP is mainly caused
by a systemic response rather than a local response atthe joint level, because many inflammatory molecules
show higher SF levels than serum levels. SF monocytes
and lymphocytes are accessorial sources of SF CRP;
however, the main source of SF CRP is an inflow of
Figure 5 The effect of FcγRs on the CRP-induced osteoclastogenesis from monocytes. (A) CD14+ monocytes, which were isolated from
peripheral blood, were cultured with 25 ng/mL of M-CSF and 1.0 μg/mL of CRP in the presence of anti-CD64 (FcγRI inhibitor), anti-CD32 (FcγRIIa
inhibitor), or anti-CD16 (FcγRIIb inhibitor). After 21 days of culture, TRAP+ multinucleated cells were counted. The inhibition of FcγRI, FcγRIIa, and
FcγRIIb decreased CRP-induced osteoclastogenesis. The figure represents one of three independent experiments (original magnification: 200×).
(B) The gene expression of osteoclast fusion proteins such as DC-STAMP and MFR were measured from differentiated osteoclasts using real-time
PCR. The expression of DC-STAMP decreased significantly with the inhibition of FcγRI, FcγRIIa, and FcγRIIb, and the expression of MFR decreased
significantly with the inhibition of FcγRI and FcγRIIa. (C) The gene expressions of osteoclast markers such as cathepsin K, RANK, MMP-9, and
CTR were measured from differentiated osteoclasts using real-time PCR. The gene expressions of cathepsin K, RANKL, and MMP-9 decreased
significantly with the inhibition of FcγRI, FcγRIIa, and FcγRIIb. The expression of CTR mRNA decreased with the inhibition of FcγRI. The data
represents the mean ± SEM for three independent experiments; *P <0.05 and **P <0.01. CRP, C-reactive protein; CTR, calcitonin receptor; DC-STAMP,
dendritic cell-specific transmembrane protein; FcγR, Fcgamma receptors; M-CSF, macrophage colony-stimulating factor; MFR, macrophage fusion
receptor; MMP, matrix metalloproteinases; RANKL, receptor activator of nuclear factor kappa-B ligand; SEM, standard error of the mean.
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Figure 6 Immunoglobulin G (IgG)-induced RANKL expression in peripheral blood monocytes and osteoclast differentiation. (A) After
peripheral blood CD14+ monocytes were cultured with 0 to 20 mg/mL of intravenous immunoglobulin (IVIg) for 72 h, the expression of RANKL
mRNA was determined using real-time PCR. The expression of RANKL mRNA increased at 1.0 mg/mL of IVIg. (B) Peripheral blood CD14+
monocytes were pretreated with anti-CD64, anti-CD32, or anti-CD16 for 1 h and were cultured with 1 mg/mL of IVIg for 72 h. The expression
of RANKL mRNA was determined using real-time PCR. The expression of RANKL mRNA decreased after inhibition of FcγRI, FcγRIIa, and FcγRIIb.
(C) CD14+ monocytes, which were isolated from peripheral blood, were cultured with 25 ng/mL of M-CSF and 0 to 1.0 mg/mL of IVIg. After
21 days of culture, TRAP-positive multinucleated cells were counted and bone resorbing function was assessed. TRAP+ multinucleated osteoclasts
were differentiated from the monocytes and bone resorbing function was induced by IVIg, however, the effect was smaller than that of CRP.
The figures represent one of three independent experiments (original magnification: 200×). The data represents the mean ± SEM for three
independent experiments; *P <0.05, **P <0.01. CRP, C-reactive protein; FcγR, Fcgamma receptors; M-CSF, macrophage colony-stimulating factor;
RANKL, receptor activator of nuclear factor kappa-B ligand; SEM, standard error of the mean; TRAP, tartrate-resistant acid phosphatase.
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serum CRP level proves to be a useful marker in RA be-
cause it reflects both systemic and local inflammatory
responses.
To determine the direct pathogenic effect of CRP on
bone destruction in RA, we studied the effect of CRP onthe production of RANKL from monocytes, which is a
key molecule in osteoclastogenesis in RA. When CD14+
monocytes were isolated from peripheral blood and stimu-
lated with CRP, the expression and production of RANKL
increased. CRP did not increase the production of IL-1β,
IL-6, and TNF-α in monocyte culture, indicating that CRP
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phenomenon is not mediated by the proinflammatory cy-
tokines, which are known to stimulate CRP production in
hepatocytes and induce RANKL expression in RA.
To determine the direct effect of CRP on osteoclast
differentiation, peripheral blood monocytes were cultured
with CRP and M-CSF in the absence of RANKL. In RA,
bone destruction is mainly regulated by osteoclasts, and
RANKL is an essential molecule for the induction of osteo-
clastogenesis in peripheral blood monocytes [27]. However,
we found that CRP, in combination with M-CSF, induced
osteoclast differentiation in the absence of RANKL, an ob-
servation suggesting that CRP could substitute for RANKL
in the induction of osteoclastogenesis. We suppose that
CRP is induced by IL-6, IL-1, and TNF-α in the inflam-
matory condition of RA, and CRP independently stimu-
lates RANKL expression and osteoclast differentiation
from osteoclast precursors in synovial tissues and syn-
ovial fluid. It is possible that CRP could potentiate the
osteoclastic effect of the proinflammatory cytokines,
and further investigation is required to evaluate the
connection to RA synovial tissues.
Finally, we investigated the pathways of CRP-induced
RANKL expression and osteoclastogenesis. On monocytes
and macrophages, CRP is mostly mediated by FcγR-
dependent pathways. High-affinity receptor FcγRI (CD64)
and low-affinity receptor FcγRIIA (CD32) are activating
receptors, while low-affinity receptor FcγRIIB (CD16) is
an inhibitory receptor [28,29]. CRP activates FcγRs, which
phosphorylate immunoreceptor tyrosine-based activating
motifs, causing the activation of Syk (spleen tyrosine kin-
ase) and in turn initiating downstream signaling cascades
[29]. The interaction of CRP and FcγRs promotes survival
and proliferation of macrophages and enhances the release
of proinflammatory molecules through stimulation of
MMPs, MCP-1, and M-CSF expression and inhibition of
IL-10 secretion [30-34]. In RA animal models, FcγRs
directly mediate cartilage destruction. FcγRIIb−/− and
FcγRI/II/III−/− mice enhance bone erosion and osteo-
clast numbers as well as severe joint inflammation in
antigen-induced arthritis, suggesting that the net effect
of FcγRs on bony destruction could be primarily medi-
ated by downregulated FcγRIIb [35-37]. In this study,
the blockage of all three FcγRs partially abrogated the
CRP-induced RANKL expression and osteoclast differ-
entiation through the inhibition of osteoclast fusion
proteins such as DC-STAMP and MFR, suggesting all
three receptors were involved in the osteoclastogenic ef-
fect of CRP. The process of bone destruction in RA is
very intricate, involving complex interactions between
various cytokines and cells. The relationship between
CRP and FcγRs requires further exploration in terms of
the network effects and the mechanisms of CRP and
FcγRs in osteoclastogenesis in RA.Conclusions
CRP induced RANKL expression and stimulated osteo-
clastogenesis and bone resorbing function from osteoclast
precursors. In treating patients with RA, the significance
of reduced serum CRP levels lies not only in controlling
disease activity, but also in providing the possibility for
prevention of bony destruction.
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